<DOC>
	<DOCNO>NCT02175342</DOCNO>
	<brief_summary>This pharmacodynamic pharmacokinetic dose-ranging study aim determine optimal dose tiotropium inhaled solution Respimat device day three week patient COPD .</brief_summary>
	<brief_title>Pharmacodynamic Pharmacokinetic Dose Ranging Study Tiotropium Bromide Administered Via Respimat Device Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Age : ≥ 40 year ; 2 . Diagnosis COPD meet follow criterion : 1 . Relatively stable , moderate severe airway obstruction , 2 . Baseline 30 % ≤ FEV1 ≤ 65 % predict normal value , predict normal value base guideline standardize lung function test European Community Coal Steel ( ECCS ) , 3 . Baseline FEV1/ force expiratory vital capacity ( FEVC ) ≤ 70 % ; 3 . Smoking history ≥ 10 packyears ( p.y. ) . A p.y . define equivalent smoke one pack cigarettes per day one year ; 4 . Male female ; 5 . Ability train proper use Respimat Handihaler ; 6 . Ability train performance technically satisfactory pulmonary function test ; 7 . Ability provide write informed consent 8 . Patient affiliate Social Security System 1 . History asthma , allergic rhinitis atopy blood eosinophil count 600/mm³ 2 . Changes therapeutic ( pulmonary ) plan within last six week prior Screening Visit ; 3 . Treatment cromolyn/nedocromil sodium ; 4 . Treatment antihistamine ( H1 receptor antagonist ) ; 5 . A low respiratory tract infection exacerbation past six week prior Screening Visit ; 6 . Regular use daytime oxygen therapy ; 7 . Treatment oral corticosteroid medication initiate modify within last six week daily dose &gt; 10 mg prednisone equivalent ; 8 . History life threaten pulmonary obstruction , cystic fibrosis bronchiectasis 9 . Patients undergone thoracotomy pulmonary resection ; 10 . History clinically significant cardiovascular , renal neurologic , liver endocrine dysfunction . A clinically significant disease define one opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 11 . Patients recent ( ≤ one year ) history myocardial infarction , heart failure patient cardiac arrhythmia require drug therapy ; 12 . Tuberculosis indication treatment ; 13 . History cancer within last five year . Patients treat basal cell carcinoma allow : 14 . Current psychiatric disorder ; 15 . Patients know symptomatic prostatic hypertrophy bladder neck obstruction ; 16 . Patients history glaucoma increase intraocular pressure ; 17 . Patients clinically significant abnormal baseline haematology blood chemistry , abnormality defines disease list exclusion criterion ; 18 . Patients 1. glutamyloxaloacetic transaminase/glutamylpyruvic transaminase ( SGOT/SGPT ) : &gt; 200 % upper limit normal range ( ULN , ) 2. bilirubin : &gt; 150 % ULN , 3. creatinine : &gt; 125 % ULN ; 19 . Intolerance aerosolise anticholinergic containing product , and/or hypersensitivity benzalkonium chloride , lactose component inhalation capsule delivery system ; 20 . Betablocker medication ; 21 . Concomitant recent ( within last month ) use investigational drug ; 22 . History drug abuse and/or alcoholism ; 23 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( urinary pregnancy test screening ) ; 24 . Previous participation study ( i.e . allocate randomised treatment number ) ; 25 . Patients deprive freedom judicial administrative decision ; 26 . Minors , adult guardianship ; 27 . Persons medical social establishment ; 28 . Patients emergency situation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>